
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Mankind Pharma obtained all regulatory approvals, including from CCI, for its ₹13,630 crore acquisition of Bharat Serums and Vaccines. The transaction involves acquiring a 100% stake in BSV.
Mankind Pharma Ltd. has successfully received all the necessary regulatory approvals, including the green light from the Competition Commission of India (CCI), to complete its 100% acquisition of Bharat Serums and Vaccines Ltd. (BSV). The acquisition, valued at ₹13,630 crore, marks a significant milestone in Mankind Pharma's expansion strategy in the biopharmaceutical and vaccine sector.
The company announced the execution of a Share Purchase Agreement on 25 July 2024. The agreement involves the acquisition of Bharat Serums and Vaccines Ltd. from Ansamira Ltd. and Miransa Ltd., affiliates of funds managed by Advent International, along with minority shareholders Bhaskar Iyer and Abhijit Mukherjee. The deal includes acquiring 100% of BSV's shares, making Mankind Pharma a key player in the biopharmaceutical market.
Mankind Pharma disclosed that the transaction is now subject to the completion of customary conditions precedent, as detailed in the Share Purchase Agreements. However, with regulatory hurdles cleared, the acquisition is expected to proceed smoothly.
Bharat Serums and Vaccines Ltd. specialises in the development and manufacturing of biopharmaceuticals, vaccines, and critical-care products, with a portfolio that includes treatments for immunology, oncology, and gynaecology. The acquisition aligns with Mankind Pharma's strategy of expanding its product offerings and tapping into high-growth therapeutic areas. This acquisition is expected to strengthen Mankind Pharma's position in the Indian and global pharmaceutical markets.
The acquisition deal is valued at ₹13,630 crore, positioning it as one of the largest in the Indian pharmaceutical industry this year. The acquisition is anticipated to drive growth for Mankind Pharma by enhancing its presence in key markets and diversifying its product portfolio. Investors will closely watch Mankind Pharma's share price as the company integrates BSV into its operations and explores potential synergies.
Mankind Pharma’s acquisition of Bharat Serums and Vaccines Ltd. is a strategic move that solidifies its position in the biopharmaceutical sector. With regulatory approvals secured, the completion of the transaction is on the horizon, promising growth and market expansion.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading